Skip to main content
. 2010 Apr 24;4(4):335–346. doi: 10.1016/j.molonc.2010.04.008

Figure 4.

Figure 4

Survival in patients with AML and those with AML with associated SM (SM‐AML). Survival of patients with de novo acute myeloid leukemia (AML) (green), patients with secondary AML (blue), and patients with AML and associated systemic mastoyctosis (SM‐AML) (red) was calculated by the method of Kaplan and Meyer. Survival was calculated from the time point of first diagnosis of AML (A) and from the time point of first diagnosis of SM or AML (whatever first diagnosed) (B).